- Adjusted EBITDA was $10.4 million compared to $21.5 million in the prior year quarter.
- Castle Biosciences reported Q2 2025 revenue of $86.2 million, a 1% decrease compared to Q2 2024, driven by a $12.5 million decline in dermatological test revenue offset by an $11.7 million increase in non-dermatological tests.
- DecisionDx-SCC revenue for Q2 2025 was estimated just above $15 million; excluding this test, normalized revenue growth was approximately 23%.
- Gross margin was 77.3% in Q2 2025 compared to 80.7% in Q2 2024; adjusted gross margin was 79.5% versus 83.2% in the prior year period.
- Net cash provided by operating activities was $20.8 million for Q2 2025 and $14.8 million for the first half of 2025; cash, cash equivalents, and marketable securities totaled $275.9 million as of June 30, 2025.
- Net income for Q2 2025 was $4.5 million, down from $8.9 million in Q2 2024; diluted EPS was $0.15 versus $0.31.
- Operating expenses increased to $90.4 million from $82 million, driven by higher sales and marketing, general and administrative, and cost of sales expenses due to personnel and lab service cost increases.
Related items and other data are not available for this feed item.
Dafinchi